These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 16000567)

  • 1. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.
    Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O
    Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.
    Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L
    J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.
    Migaldi M; Sgambato A; Garagnani L; Ardito R; Ferrari P; De Gaetani C; Cittadini A; Trentini GP
    Clin Cancer Res; 2000 Aug; 6(8):3131-8. PubMed ID: 10955794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
    Krüger S; Lange I; Kausch I; Feller AC
    Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
    Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
    J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
    Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
    J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
    Schlichtholz B; Presler M; Matuszewski M
    Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of nuclear p53 and tumor progression in bladder cancer.
    Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ
    N Engl J Med; 1994 Nov; 331(19):1259-64. PubMed ID: 7935683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
    Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
    Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy.
    Pfister C; Flaman JM; Dunet F; Grise P; Frebourg T
    J Urol; 1999 Jul; 162(1):69-73. PubMed ID: 10379742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.